| Bioactivity | D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (Ki: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism[1]. |
| Target | 46.5 nM and 691 nM (D3R/MOR) |
| Name | D3R/MOR antagonist 1 |
| Formula | C22H27Cl2N3O |
| Molar Mass | 420.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bonifazi A, et al. Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D3 (D3R) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics. J Med Chem. 2023 Aug 10;66(15):10304-10341. |
D3R/MOR antagonist 1
CAS: F: C22H27Cl2N3O W: 420.38
D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (Ki: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.